Evaluation of Treatment Effect of Low FODMAP Diet in Treatment of IBS Patients

NCT05144204 | Unknown DMC

• 1 other identifier: 2018-07-023B
• Study Type: interventional
• Target: 30
• Locations: 0 countries
• Sites: N/A

Brief Summary

Irritable bowel syndrome (IBS) is a common functional gastrointestinal disorder, affecting 15% of the population. IBS is characterized by recurrent abdominal pain/discomfort without identifiable organic lesions. The pathophysiology of IBS can be multi factors which included immune activation/inflammatory reactions, visceral hypersensitivity, gastrointestinal dysmotility, changes in gut microflora, brain-gut dysfunction and food intolerance. Many short-chain carbohydrates can induce abdominal symptoms, and these carbohydrates were called, Fermentable, Oligosaccharides, Disaccharides and Monosaccharides and Polyols (FODMAPs). Around 50- 86% of the IBS patients will have a clinically meaningful response to the low-FODMAP diet. To evaluate the efficacy of low FODMAP diet. Experimental design: Health control and patients meeting the ROME III criteria for IBS will be enrolled in this study. The basic profiles, patient characteristics, intestinal microbiota profiles and MRI images will be obtained before and after low FODMAP diet intervention.

Conditions

Irritable Bowel Syndrome

Keywords

Low FODMAP diet

Outcome Measures

Primary Outcomes (1)

• irritable bowel syndrome Severity Scale (IBS-SS)

  The primary endpoint is the variable used to assess the main objective, the efficacy of low FODMAP diet on gastrointestinal symptoms in IBS (focusing on the elimination phase) change from baseline after 6-8 weeks. The variables used will be the symptom scores of several symptom questionnaires. Ultimately, the efficacy of the diet is based on improvement of symptom scores. Improvement is defined as a 50-point drop on the Irritable Bowel Syndrome Symptom Severity Scale (IBS-SSS). In this questionnaire, each quesiton is scored from 0-100, with a maximum total score of 500. Patients reporting scores \<50 are defined as non-IBS individuals, a score from 50-175 indicated mild disease, 175-300 moderate and \>300 severe.

  Baseline, end of study approximately 6 to 8 weeks ]

Study Arms (1)

Irritable Bowel Syndrome Patients

EXPERIMENTAL

Behavioral: Low FODMAP diet

Interventions

Low FODMAP diet BEHAVIORAL

Low FODMAP diet instruction to irritable bowel syndrome patients.

Irritable Bowel Syndrome Patients

Eligibility Criteria

• Age: 20 Years - 65 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patients are eligible for the study if all of the following criteria are met:
• Patients with irritable bowel syndrome as per Rome IV diagnostic criteria Symptom characteristics of IBS according to Rome III and IV criteria
• Patients must provide witnessed written informed consent prior to any study procedures being performed
• Patients aged between 20-65 years
• Male or female patients

You may not qualify if:

• Unable to provide or understand written informed consent.
• Pregnancy.
• Receiving antibiotics or narcotics within 90 days prior to enrollment.
• Receiving new prebiotics, probiotics within 90 days prior to enrollment.
• Current infection.
• History of inflammatory bowel disease.
• Thyroid disease.
• Major psychiatric disorders, including clinical anxiety or depression and previous use of anxiolytics and antidepressants.
• Previous stroke, intracerebral hemorrhage, or central nervous system diseases.
• Malignancy.

Sponsors & Collaborators

• Taipei Veterans General Hospital, Taiwan: lead

MeSH Terms

Conditions

Irritable Bowel Syndrome

Interventions

FODMAP Diet

Condition Hierarchy (Ancestors)

Colonic Diseases, Functional; Colonic Diseases; Intestinal Diseases; Gastrointestinal Diseases; Digestive System Diseases

Intervention Hierarchy (Ancestors)

Elimination Diets; Diet; Nutritional Physiological Phenomena; Diet, Food, and Nutrition; Physiological Phenomena

Central Study Contacts

Ching-Liang Lu

CONTACT

886228712121; cllu@vghtpe.gov.tw

Po-Shan Wu

CONTACT

886228712121; pswu2@vghtpe.gov.tw

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: OTHER
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER GOV
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 6, 2021
• First Posted: December 3, 2021
• Study Start: December 1, 2021
• Primary Completion: May 31, 2022
• Study Completion: December 31, 2023
• Last Updated: December 3, 2021

Record last verified: 2021-11